BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 19292797)

  • 1. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery.
    Boland GP; Chan KC; Knox WF; Roberts SA; Bundred NJ
    Br J Surg; 2003 Apr; 90(4):426-32. PubMed ID: 12673743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ.
    MacAusland SG; Hepel JT; Chong FK; Galper SL; Gass JS; Ruthazer R; Wazer DE
    Cancer; 2007 Dec; 110(12):2648-53. PubMed ID: 17960606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis.
    Asjoe FT; Altintas S; Huizing MT; Colpaert C; Marck EV; Vermorken JB; Tjalma WA
    Breast J; 2007; 13(4):359-67. PubMed ID: 17593040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
    Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
    Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience.
    Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R
    Breast J; 2005; 11(4):242-7. PubMed ID: 15982389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of predictive factors, particularly the Van Nuys index, of local recurrence in ductal carcinoma in situ of the breast: study of 166 cases with conservative treatment and review of the literature].
    Denoux Y; Marnay J; Crouet H; Boute V; Delozier T; Vie B; Chasle J
    Bull Cancer; 2001 Apr; 88(4):419-25. PubMed ID: 11371378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
    Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
    Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
    Maxhimer JB; Pesce CE; Stewart RA; Gattuso P; Prinz RA; Xu X
    J Am Coll Surg; 2005 Mar; 200(3):328-35. PubMed ID: 15737842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
    Zhou L; Wang Y; Song X; Du JW; Pei F; Huang LP; Wang WY; Liu ZB; Pan RQ
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3035-8. PubMed ID: 16324401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of local recurrence following excision alone for ductal carcinoma in situ.
    Hetelekidis S; Collins L; Silver B; Manola J; Gelman R; Cooper A; Lester S; Lyons JA; Harris JR; Schnitt SJ
    Cancer; 1999 Jan; 85(2):427-31. PubMed ID: 10023711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study.
    Benitez PR; Streeter O; Vicini F; Mehta V; Quiet C; Kuske R; Hayes MK; Arthur D; Kuerer H; Freedman G; Keisch M; Dipetrillo T; Khan D; Hudes R
    Am J Surg; 2006 Oct; 192(4):427-33. PubMed ID: 16978943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
    Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
    Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.